TScan Therapeutics, Inc. Quarterly Return On Equity in % from Q4 2021 to Q3 2024

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
TScan Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from Q4 2021 to Q3 2024.
  • TScan Therapeutics, Inc. Return On Equity for the quarter ending September 30, 2024 was -58.7 %, a 10.7% increase year-over-year.
  • TScan Therapeutics, Inc. annual Return On Equity for 2023 was -60.7 %, a 13% decline from 2022.
  • TScan Therapeutics, Inc. annual Return On Equity for 2022 was -53.7 %, a 37.9% increase from 2021.
  • TScan Therapeutics, Inc. annual Return On Equity for 2021 was -86.5 %, a 205% decline from 2020.
Return On Equity, Quarterly (%)
Return On Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q3 2024 -58.7 +7.07 +10.7% Jul 1, 2024 Sep 30, 2024
Q2 2024 -59.8 +7.48 +11.1% Apr 1, 2024 Jun 30, 2024
Q1 2024 -61.1 +7.11 +10.4% Jan 1, 2024 Mar 31, 2024
Q4 2023 -60.7 -6.96 -13% Oct 1, 2023 Dec 31, 2023
Q3 2023 -65.8 -21.3 -47.9% Jul 1, 2023 Sep 30, 2023
Q2 2023 -67.3 -27.3 -68.1% Apr 1, 2023 Jun 30, 2023
Q1 2023 -68.2 -14.1 -26.1% Jan 1, 2023 Mar 31, 2023
Q4 2022 -53.7 +32.8 +37.9% Oct 1, 2022 Dec 31, 2022
Q3 2022 -44.5 Jul 1, 2022 Sep 30, 2022
Q2 2022 -40.1 Apr 1, 2022 Jun 30, 2022
Q1 2022 -54.1 Jan 1, 2022 Mar 31, 2022
Q4 2021 -86.5 Oct 1, 2021 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.